Brain axis. This review therefore, investigates whether the administration of prebiotics is efficacious in attenuating age-related neurodegeneration.

Methods 2675 studies from MEDLINE, Embase, Scopus, Web of Science and Cochrane library were searched for in vivo studies using equivalent combinations of 'prebiotics' and 'age-related neurodegeneration' in concordance with PRISMA guidelines. Quantitative outcomes such as Morris Water Maze (MWM), a cognitive-behavioural task, were examined and pooled with Forest Plots for overall effect (95% CI) and heterogeneity (I^2). Weighted meta-regression of the prebiotic-neurodegeneration association with other continuous parameters such as treatment duration, study sample size and year of publication were assessed for potential confounding associations.

Risk of Bias (RoB) for animal studies was assessed by the SYRCLE tool. Publication bias was analysed by the Begg-Mazumdar funnel plot. The potential conflict of interest in the source of funding was examined by subgroup analysis.

Results 5 human studies on aged healthy volunteers were found. 23 animal studies were identified, with 9 animal studies having comparable quantitative results (149 subjects). Overall results in figure 1 demonstrate a 17.69 sec (11.71–23.67; I^2 : 96.8) improvement in MWM Escape Latency, suggesting an improvement in neurocognitive function in animal models. Meta-regression revealed that prebiotic-neurodegeneration association is independent from duration of treatment ($p=0.202$), year of publication ($p=0.184$); and sample size ($p=0.0685$).

RoB analysis of animal studies on prebiotics shows that there is a risk for bias in terms of study personnel blinding and random housing and outcome assessment of subjects. An asymmetric distribution that is largely beyond the 95% CIs was observed in the Begg-Mazumdar funnel plot. 4 privately-funded studies had significantly weaker association of 12.67s (3.18–22.17) than 5 government-funded studies 21.61s (15.26–27.97).

Conclusions Weak evidence suggests that prebiotic supplementation is useful in attenuating age-related neurocognitive decline, thus requiring more clinical trials to evidence its true efficacy.

IDDF2020-ABS-0207

EFFICACY AND SAFETY OF ENDOSCOPIC BALLOON DILATATION COMBINED WITH LOCAL INJECTION OF BETAMETHASONE IN THE TREATMENT OF INTESTINAL STENOSIS IN CROHN'S DISEASE

¹Junrong Chen*, ²Jiachen Sun, ¹Xiang Peng, ¹Tao Liu, ¹Min Zhang, ¹Min Zhi. ¹Department of Gastroenterology, The Sixth Affiliated, Sun Yat-sen University, China; ²Department of Gastrointestinal Endoscopy, The Sixth Affiliated, Sun Yat-sen University, China

10.1136/gutjnl-2020-IDDF.121

Background To evaluate the efficacy and safety of endoscopic balloon dilatation (EBD) combined with local injection of betamethasone in the treatment of intestinal stenosis in Crohn's disease (CD).

Methods A total of 51 patients with CD intestinal stenosis treated with EBD in the Sixth Affiliated Hospital of Sun Yat-sen University from August 2013 to June 2020 were collected, including 38 patients treated with EBD alone and 13 patients treated with EBD combined with local injection of betamethasone. The efficacy and safety of the two treatment methods were compared.

Results Among the 51 patients, there were 36 males and 15 females, the median age was 32 years old, average body mass index (BMI) was 19.23, combined with the perianal disease was 54.9%, follow-up time ranged from 0.4 to 78.6 months, and median follow-up time was 15.7 months. There was no significant difference in the disease course, activity, extraintestinal manifestations, perianal disease, endoscopic stenosis length, proximal CTE dilation diameter and other general information. In terms of treatment effect, there was no significant difference in treatment success rate (100% vs. 94.7%, $P=1.000$), symptom relief rate (92.3% vs. 84.2%, $P=0.440$) or complication rate (0 vs. 5.3%, $P=1.000$) in the EBD combined with local injection of betamethasone. In the follow-up after treatment, it was found that the EBD combined with local injection of betamethasone group had fewer CD drug upgrades (7.7% vs. 18.4%, $P=0.329$), a lower rate of endoscopic expansion (30.8% vs. 39.5%, $P=0.575$), and a lower rate of surgery (7.7% vs. 15.8%, $P=0.440$).

Conclusions Ileocecal valve and colorectal anastomosis is the most common CD merger of the digestive tract stenosis position, EBD combined with local injections of betamethasone treatment of digestive tract stenosis type CD curative effect is reliable and safer. While this method on non-anastomotic stenosis, the history of intestinal fistula and the stenosis and dilation of nodular hyperplasia are not good, so it needs to be differentiated and selected in the treatment.

IDDF2020-ABS-0208

FIRST-LINE UTILIZATION OF DIRECT PERORAL CHOLANGIOSCOPY FOR LARGE COMMON BILE DUCT STONES SAVES BOTH TIME AND COST

Calvin Jianyi Koh*, Margaret Teng, Chieh Sian Koo, Bhavesh Doshi. National University Hospital, Singapore

10.1136/gutjnl-2020-IDDF.122

Background Direct Peroral Cholangioscopy (POC) is a useful adjunct to facilitate lithotripsy in the management of large common bile duct stones during endoscopic retrograde cholangiopancreatography (ERCP) but has limitations due to its cost. In our centre, POC is limited to cases where anaesthesia care is available; this is not always the case due to resource constraints.

Methods We retrospectively evaluated our ERCP cases for large stone (>10 mm) and compared cases where POC was used as the first-line vs cases where 'standard of care' was performed. Besides demographics, indications and number of ERCPs cost and use of POC were considered.

Results In the 12-month period under consideration, a total of 46 cases met the inclusion criteria, with 6 cases of POC and 40 cases of standard ERCP. Cholangitis (47.8%), and choledocholithiasis without cholangitis (45.7%) accounted for most of the cases. Of the cases with first-line POC, 33.3% required further ERCP, whereas 42.5% of the standard ERCP patients required another procedure for stone therapy. Due to the low numbers, these proportion differences did not reach statistical significance, although data collection is ongoing.

Of note, the cases with POC had a smaller average hospitalization bill size, 85.8% that of the standard ERCP. Although patients with POC had higher consumable fees, they had lower total hospitalization stay and hence had less total cost. (Figure 1).